Medios AG/€ILM1
1D1W1MYTD1Y5YMAX
About Medios AG
Medios AG, headquartered in Berlin, Germany, specializes in the supply and manufacturing of specialty pharmaceutical products, focusing on treatments for chronic and rare diseases. The company operates through two primary segments: Pharmaceutical Supply, offering a portfolio of approximately 1,000 specialty pharma drugs across therapeutic areas such as oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia; and Patient-Specific Therapies, producing individualized medications, including cytostatic infusions, antibody therapies, virostatic and antibiotic medications, and parenteral nutrition solutions, with around 400,000 preparations completed in fiscal year 2023. Founded in 2016, Medios AG has expanded its geographic footprint to include operations in Germany, the Netherlands, Belgium, and Spain. The company's strategic positioning emphasizes individualized medicine, collaborating with pharmacies, specialist practices, and pharmaceutical companies to make innovative therapies widely accessible.
- Ticker
- €ILM1
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 989
- Headquarters
- Berlin, Germany
- Website
- www.medios.ag
Medios AG Metrics
BasicAdvanced
€265M
24.14
€0.45
1.29
-
Price and volume
Market cap
€265M
Beta
1.29
52-week high
€17.42
52-week low
€10.82
Average daily volume
39K
Financial strength
Current ratio
1.837
Quick ratio
1.3
Long term debt to equity
30.37
Total debt to equity
38.205
Interest coverage (TTM)
2.25%
Profitability
EBITDA (TTM)
69.699
Gross margin (TTM)
9.18%
Net profit margin (TTM)
0.52%
Operating margin (TTM)
1.79%
Effective tax rate (TTM)
56.00%
Revenue per employee (TTM)
€2,190,000
Management effectiveness
Return on assets (TTM)
2.64%
Return on equity (TTM)
2.14%
Valuation
Price to earnings (TTM)
24.14
Price to revenue (TTM)
0.124
Price to book
0.51
Price to tangible book (TTM)
5.22
Price to free cash flow (TTM)
10.011
Free cash flow yield (TTM)
9.99%
Free cash flow per share (TTM)
1.091
Growth
Revenue change (TTM)
9.89%
Earnings per share change (TTM)
-38.70%
3-year revenue growth (CAGR)
8.95%
3-year earnings per share growth (CAGR)
-15.13%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.